17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule

January 27, 2016
A total of 17,800 hepatitis C patients were prescribed Gilead Sciences’s Sovaldi (sofosbuvir) in the six months through November, almost on a par with the 19,000 patients anticipated for its peak sales forecast, the health ministry’s early post-marketing phase vigilance...read more